NIH Announces Restructured HIV Clinical Trials Networks

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has announced the clinical investigators and institutions that will lead four NIH HIV clinical trials networks over the next seven years to conduct the innovative, efficient clinical research needed to accelerate progress against the HIV pandemic.

Marlene Cooper, ACTG/IMPAACT DMC Director

Four networks will direct, coordinate and conduct NIH-funded clinical research worldwide in close collaboration with one another, NIAID, other partner NIH Institutes and Centers, industry and non-governmental research organizations. Each network is led by a leadership and operations center (LOC) and includes a laboratory center (LC) and a statistical and data management center (SDMC). The four networks will advance four key areas of research emphasis: HIV prevention; HIV vaccines; HIV/AIDS adult therapeutics; and HIV/AIDS maternal, adolescent and pediatric therapeutics. These networks are:

  • HIV Vaccine Trials Network (HVTN)
  • HIV Prevention Trials Network (HPTN)
  • AIDS Clinical Trials Group (ACTG)
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT)

In addition, NIAID awarded grants to 35 U.S. and international institutions selected as HIV/AIDS CTUs. Each CTU supports up to eight clinical research sites. Collectively, the CTUs support 101 clinical research sites in 18 countries across North America, South America, Africa and Asia. This includes 45 sites in the United States.

The ACTG network has awarded Michael D. Hughes at the Harvard School of Public Health and Marlene Cooper at Frontier Science as the ACTG SDMC Principal Investigators.

The IMPAACT network has awarded David E. Shapiro at the Harvard School of Public Health and Marlene Cooper at Frontier Science as the IMPAACT SDMC Principal Investigators.

Read more